NOVARTIS
Novartis’ prostate cancer drug, a radiopharmaceutical, illustrates the challenge. With only a few days of shelf life, availability in remote areas requires new thinking about distribution, diagnosis and care pathways.
“ We must remove barriers – from diagnosis to treatment – so patients aren’ t excluded just because of geography,” Korab says.
“SCOPE 3 IS THE BIGGEST CHALLENGE, NOT JUST FOR US BUT FOR THE ENTIRE INDUSTRY”
Korab Zuka, Global Head of Social
Impact and CSO, Novartis sustainabilitymag. com 27